DOCSLIB.ORG

Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma cancers Review Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma Hamid Maadi 1, Mohammad Hasan Soheilifar 2, Won-Shik Choi 1, Abdolvahab Moshtaghian 3,4 and Zhixiang Wang 5,* 1 Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada; [email protected] (H.M.); [email protected] (W.-S.C.) 2 Department of Medical Laser, Medical Laser Research Center, Yara Institute, ACECR, Tehran 1315795613, Iran; [email protected] 3 Department of Molecular and Cell Biology, Faculty of Basic Sciences, University of Mazandaran, Babolsar 4741695447, Iran; [email protected] 4 Deputy of Research and Technology, Semnan University of Medical Sciences, Semnan 3514799442, Iran 5 Department of Medical Genetics and Signal, Transduction Research Group, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada * Correspondence: [email protected] Simple Summary: Overexpression of HER2 receptors have been identified in various types of cancer including breast cancer and ovarian cancer. HER2 overexpression is generally associated with poor clinical outcomes in patients with HER2-positve tumors. Trastuzumab, an antibody specifically targeting HER2 receptors, showed promising clinical benefits for patients with HER2-positive tumors. Studies show that trastuzumab suppresses HER2 receptors’ oncogenic functions in HER2-postive tumors. Moreover, trastuzumab has been shown to provoke immune responses against the HER2- amplified tumors. Citation: Maadi, H.; Soheilifar, M.H.; Choi, W.-S.; Moshtaghian, A.; Wang, Z. Trastuzumab Mechanism of Abstract: Trastuzumab as a first HER2-targeted therapy for the treatment of HER2-positive breast Action; 20 Years of Research to cancer patients was introduced in 1998. Although trastuzumab has opened a new avenue to treat Unravel a Dilemma. Cancers 2021, 13, patients with HER2-positive breast cancer and other types of cancer, some patients are not responsive 3540. https://doi.org/10.3390/ or become resistant to this treatment. So far, several mechanisms have been suggested for the mode cancers13143540 of action of trastuzumab; however, the findings regarding these mechanisms are controversial. In this review, we aimed to provide a detailed insight into the various mechanisms of action of trastuzumab. Academic Editors: Jonas Cicenas and Kylie Gorringe Keywords: trastuzumab; breast cancer; HER2; PI3K/AKT pathway; MAPK pathway Received: 6 May 2021 Accepted: 12 July 2021 Published: 15 July 2021 1. Introduction HER2 overexpression in approximately 20–30% of breast cancer (BC) patients has Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in motivated researchers for years to find a decent drug to specifically target HER2. A ® published maps and institutional affil- humanized monoclonal antibody named trastuzumab (Herceptin ), which targets the iations. extracellular domain of HER2, was developed. Since the approval of trastuzumab, many investigations have been carried out to unravel the trastuzumab mechanism of action and find an appropriate combination therapy to enhance the treatment efficacy. In this review, we aimed to shine the light on the various mechanisms through which trastuzumab exerts its anti-tumoral effects. Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. 2. From Characterization of HER2 to Developing Trastuzumab This article is an open access article distributed under the terms and In 1984, Schechter et al. isolated a gene from ethylnitrosourea-induced rat neuro/gliob- conditions of the Creative Commons lastomas and confirmed the ability of this gene to transform the NIH3T3 cells [1]. This Attribution (CC BY) license (https:// gene, which is named ‘neu’, was later shown to encode a protein with 185 kDa molecular creativecommons.org/licenses/by/ weight [1]. One year later, Coussens et al. identified and characterized a gene located at 4.0/). the human q21 region of chromosome 17 which was homologous to the rat neu gene [2]. Cancers 2021, 13, 3540. https://doi.org/10.3390/cancers13143540 https://www.mdpi.com/journal/cancers Cancers 2021, 13, x FOR PEER REVIEW 2 of 18 Cancers 2021, 13, 3540 2 of 17 gene, which is named ‘neu’, was later shown to encode a protein with 185 kDa molecular weight [1]. One year later, Coussens et al. identified and characterized a gene located at Duethe human to the q21 significant region of similarities chromosome in 17 the which protein was sequence homologous between to the rat the neu EGFR gene (HER1) [2]. andDue the to the product significant of the similaritiesneu gene, in it the was protein named sequence HER2 and between suggested the EGFR to play (HER1) a role and as a kinasethe product receptor of the at neu the gene, cell surface. it was named In 1986, HER2 Drebin and etsuggested al. demonstrated to play a role the as tumorigenic a kinase potentialreceptor at of the NIH3T3 cell surface. cells, In when 1986, transfected Drebin et al with. demonstrated the HER2 thegene tumorigenicin vivo [3]. potential They also showedof NIH3T3 that cells, treating when the transfected mice with with an antibodythe HER2 againstgene in vivo the neu [3].gene They productalso showed (anti-HER2 that antibody)treating the significantly mice with an suppresses antibody tumoragainst growth. the neu Thegene oncogenicproduct (anti function-HER2 ofantibody) HER2 was alsosignificantly confirmed suppresses by another tumor research growth. group The aboutoncogenic a year function later [of4]. HER2 In 1987, was Slamon also con- et al. foundfirmed that by another the HER2 research gene is group amplified about in a year about later 30% [4] of. In BC 1987, tumors, Slamon and et this al. found amplification that isthe significantly HER2 gene correlatedis amplified with in about poor 30% prognosis of BC tumors in BC patients, and this [ 5amplification]. In 1989, Hudziak is signifi- et al. cantly correlated with poor prognosis in BC patients [5]. In 1989, Hudziak et al. isolated a isolated a monoclonal antibody named “4D5”, which has a high specificity toward HER2, monoclonal antibody named “4D5”, which has a high specificity toward HER2, from mice from mice exposed to this receptor and showed its antiproliferative effects against SKBR3 exposed to this receptor and showed its antiproliferative effects against SKBR3 HER2- HER2-positive BC cells [6]. In 1992, Carter et al. humanized the 4D5 monoclonal antibody positive BC cells [6]. In 1992, Carter et al. humanized the 4D5 monoclonal antibody which which made it suitable for further clinical evaluation [7]. This antibody, which was named made it suitable for further clinical evaluation [7]. This antibody, which was named “Trastuzumab”, showed significant clinical benefits toward patients with HER2-positive “Trastuzumab”, showed significant clinical benefits toward patients with HER2-positive BC and increased the efficacy of conventional chemotherapies [8]. Finally, trastuzumab BC and increased the efficacy of conventional chemotherapies [8]. Finally, trastuzumab waswas approvedapproved in in the the USA USA and and Europe Europe in 1998 in 1998 and and2000, 2000,respectively respectively [9,10]. The [9,10 key]. Thefind- key findingsings related related to trastuzumab to trastuzumab history history are summarized are summarized in Figure in Figure 1. After1. Afterdemonstrating demonstrating the theclinical clinical benefits benefits of trastuzumab, of trastuzumab, many many studies studies were were carried carried out outin an in attempt an attempt to unravel to unravel thethe mechanisms mechanisms ofof action of of trastuzumab. trastuzumab. In In this this review, review, we we discuss discuss different different mechanisms mechanisms ofof action action proposedproposed for tra trastuzumab.stuzumab. FigureFigure 1. 1.Timeline Timeline of of trastuzumab trastuzumab history, history, fromfrom HER2HER2 identification identification to to demonstrating demonstrating the the clinical clinical benefits benefits of trastuzumab. of trastuzumab. 3.3. HER2 HER2 SignalingSignaling TheThe ErbB receptor receptor tyrosine tyrosine kinase kinase 2 (ErbB2 2 (ErbB2 or HER2) or HER2) belongs belongs to the ErbB to the (HER) ErbB fam- (HER) familyily of ofreceptor receptor tyrosi tyrosinene kinases kinases along along with with three three other other members members,, including including epithelial epithelial growthgrowth factorfactor receptorreceptor (EGFR), ErbB3 ErbB3 (HER3), (HER3), and and ErbB4 ErbB4 (HER4) (HER4) [11] [11. Generally,]. Generally, these these receptorsreceptors consist of of three three main main domains: domains: (1) the (1) extracellular the extracellular domain domain that contains that contains the four the foursubdomains subdomains that mediate that mediate HER receptor HER receptor ligand-dependent ligand-dependent or -independent or -independent dimerization, dimer- ization,(2) transmembrane(2) transmembrane domain domainthat connects that connectsextracellular extracellular and cytoplasmic and cytoplasmic domains, and domains, (3) andthe (3)C-terminal the C-terminal cytoplasmic cytoplasmic domain that domain contains that containstyrosine kinase tyrosine and kinase regulatory and regulatorysubdo- subdomainsmains [12]. Upon [12]. Uponthe binding the binding of HER of-specific HER-specific ligands ligands to HER to receptors, HER receptors, these receptors these recep- torsform form homo homo-- or heterodimers. or heterodimers. Subsequently, Subsequently, certain certain tyrosine tyrosine residues residues in cytoplasmic
Load more

Recommended publications
  • Overexpression of Syk Tyrosine Kinase in Peripheral T-Cell Lymphomas
    Leukemia (2008) 22, 1139–1143 & 2008 Nature Publishing Group All rights reserved 0887-6924/08 $30.00 www.nature.com/leu ORIGINAL ARTICLE Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas AL Feldman1, DX Sun1, ME Law1, AJ Novak2, AD Attygalle3, EC Thorland1, SR Fink1, JA Vrana1, BL Caron1, WG Morice1, ED Remstein1, KL Grogg1, PJ Kurtin1, WR Macon1 and A Dogan1 1Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; 2Department of Hematology, Mayo Clinic, Rochester, MN, USA and 3Department of Histopathology, Royal Marsden Hospital, London, UK Peripheral T-cell lymphomas (PTCLs) are fatal in the majority of Materials and methods patients and novel treatments, such as protein tyrosine kinase (PTK) inhibition, are needed. The recent finding of SYK/ITK translocations in rare PTCLs led us to examine the expression Cases of Syk PTK in 141 PTCLs. Syk was positive by immuno- We studied specimens from 141 patients with PTCL diagnosed 15 histochemistry (IHC) in 133 PTCLs (94%), whereas normal by WHO criteria. There were 86 men and 55 women of a T cells were negative. Western blot on frozen tissue (n ¼ 6) mean age of 59 years (range, 5–88 years). The study was and flow cytometry on cell suspensions (n ¼ 4) correlated with approved by the Institutional Review Board and the Biospeci- IHC results in paraffin. Additionally, western blot demonstrated mens Committee of Mayo Clinic. All patients provided informed that Syk-positive PTCLs show tyrosine (525/526) phosphory- lation, known to be required for Syk activation. Fluorescence consent for the use of their tissues for research purposes.
    [Show full text]
  • Pertuzumab and Trastuzumab: the Rationale Way to Synergy
    Anais da Academia Brasileira de Ciências (2016) 88(1 Suppl.): 565-577 (Annals of the Brazilian Academy of Sciences) Printed version ISSN 0001-3765 / Online version ISSN 1678-2690 http://dx.doi.org/10.1590/0001-3765201620150178 www.scielo.br/aabc Pertuzumab and trastuzumab: the rationale way to synergy SANDRINE RICHARD1, FRÉDÉRIC SELLE1, JEAN-PIERRE LOTZ1,2, AHMED KHALIL1, JOSEPH GLIGOROV1,2 and DANIELE G. SOARES1 1Medical Oncology Department, APREC (Alliance Pour la Recherche En Cancérologie), Tenon Hospital (Hôpitaux Universitaires de l’Est-Parisien, AP-HP), rue de la Chine, 75020 Paris, France 2Institut Universitaire de Cancérologie Université Pierre et Marie Curie (IUC-UPMC Univ Paris 06), Sorbonne Universités, 4 place Jussieu, 75005 Paris, France Manuscript received on March 13, 2015; accepted for publication on May 5, 2015 ABSTRACT It has now been 15 years since the HER2-targeted monoclonal antibody trastuzumab was introduced in clinical and revolutionized the treatment of HER2-positive breast cancer patients. Despite this achievement, most patients with HER2-positive metastatic breast cancer still show progression of their disease, highlighting the need for new therapies. The continuous interest in novel targeted agents led to the development of pertuzumab, the first in a new class of agents, the HER dimerization inhibitors. Pertuzumab is a novel recombinant humanized antibody directed against extracellular domain II of HER2 protein that is required for the heterodimerization of HER2 with other HER receptors, leading to the activation of downstream signalling pathways. Pertuzumab combined with trastuzumab plus docetaxel was approved for the first-line treatment of patients with HER2-positive metastatic breast cancer and is currently used as a standard of care in this indication.
    [Show full text]
  • Trastuzumab, Biosimilars, Trastuzumab-Hyaluronidase
    Clinical Policy: Trastuzumab, Biosimilars, Trastuzumab-Hyaluronidase Reference Number: CP.PHAR.228 Effective Date: 06.01.16 Last Review Date: 05.20 Coding Implications Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Trastuzumab (Herceptin®) is a human epidermal growth factor receptor 2 (HER2)/neu receptor antagonist. Trastuzumab-dkst (Ogivri™), trastuzumab-pkrb (Herzuma®), trastuzumab-dttb (Ontruzant®), trastuzumab-qyyp (Trazimera™), and trastuzumab-anns (Kanjinti™) are Herceptin biosimilars. Trastuzumab-hyaluronidase-oysk (Herceptin Hylecta™) is a combination of trastuzumab and hyaluronidase, an endoglycosidase. FDA Approved Indication(s) Indications* Description Herceptin, Herzuma Herceptin Ogivri, Hylecta Ontruzant, Trazimera, Kanjinti Adjuvant For adjuvant As part of a treatment X X X breast cancer treatment of regimen consisting of HER2- doxorubicin, overexpressing cyclophosphamide, node positive and either paclitaxel or node or docetaxel negative As part of a treatment X X X (ER/PR regimen with negative or docetaxel and with one high carboplatin risk feature) As a single agent X X X breast cancer: following multi- modality anthracycline based therapy Metastatic In combination with paclitaxel for first- X X X breast cancer line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of X X X HER2-overexpressing breast cancer in patients who have received one or more Page 1 of 13
    [Show full text]
  • Erb‑B2 Receptor Tyrosine Kinase 2 Is Negatively Regulated by the P53‑Responsive Microrna‑3184‑5P in Cervical Cancer Cells
    ONCOLOGY REPORTS 45: 95-106, 2021 Erb‑B2 Receptor Tyrosine Kinase 2 is negatively regulated by the p53‑responsive microRNA‑3184‑5p in cervical cancer cells HONGLI LIU1, YUZHI LI1, JING ZHANG1, NAN WU2, FEI LIU2, LIHUA WANG1, YUAN ZHANG1, JING LIU1, XUAN ZHANG3, SUYANG GUO1 and HONGTAO WANG4 Departments of 1Gynecological Oncology and 2Respiration and Anhui Clinical and Preclinical Key Laboratory of Respiratory Disease, First Affiliated Hospital of Bengbu Medical College; Departments of3 Gynecological Oncology and 4Immunology and Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, Bengbu, Anhui 233030, P.R. China Received November 30, 2019; Accepted October 2, 2020 DOI: 10.3892/or.2020.7862 Abstract. The oncogenic role of Erb-B2 Receptor Tyrosine Introduction Kinase 2 (ERBB2) has been identified in several types of cancer, but less is known on its function and mechanism of Among women, cervical cancer is ranked 4th in global action in cervical cancer cells. The present study employed cancer-associated deaths (1), with over half a million deaths a multipronged approach to investigate the role of ERBB2 in in 2012 (2). Cervical cancer can be broadly categorized into cervical cancer. ERBB2 and microRNA (miR)-3184-5p expres- squamous cell carcinoma, which constitutes the majority of sion was assessed in patient-derived cervical cancer biopsy cases (70-80%) or adenocarcinoma, which comprises 10-15% tissues, revealing that higher levels of ERBB2 and lower levels of cases (3). Cervical cancer is frequently caused by the of miR-3184-5p were associated with clinicopathological indi- oncovirus human papillomavirus (HPV), mainly by types cators of cervical cancer progression.
    [Show full text]
  • ITK Inhibitors for the Treatment of T-Cell Lymphoproliferative Disorders John C
    ITK Inhibitors for the Treatment of T-Cell Lymphoproliferative Disorders John C. Reneau, MD, PhD1, Steven R. Hwang, MD2, Carlos A. Murga-Zamalloa, MD1, Joseph J. Buggy, PhD3, James W. Janc, PhD3 and Ryan A. Wilcox, MD, PhD1 1University of Michigan, Ann Arbor, MI; 2Mayo Clinic, Rochester, MN; 3Corvus Pharmaceuticals, Inc., Burlingame, CA Introduction Results and Methods Conclusions • T-cell lymphomas (TCL) comprise a rare, aggressive, and Table 1: CPI-818 specifically inhibits ITK Figure 2: CPI-818 has minimal effect on normal T cells • CPI-818 is a potent ITK specific inhibitor, while CPI-893 inhibits both heterogeneous subtype of non-Hodgkin lymphoma B IC50 (nM) A ITK and RLK • Outcomes for patients with TCL remain poor and novel therapies are ITK RLK • Normal T cells express both ITK and RLK which can compensate for needed CPI-818 (ITKi) 2.3 260 inhibition of ITK function CPI-893 (ITK/RLKi) 0.36 0.4 • Engagement of the T-cell receptor (TCR) in malignant T-cells leads to • Malignant T cells almost exclusively express ITK, or express RLK at Kinome screening was performed for CPI-818 (ITKi) and CPI-893 (ITK/RLKi). CPI-818 (ITKi) had high interleukin-2-inudcible T-cell kinase (ITK) dependent activation of NF- specificity for ITK over RLK (IC50 2.3 nM and 260 nM, respectively). In contrast CPI-893 (ITK/RLKi) had a very low levels high affinity for both ITK and RLK (IC50 0.36 nM and 0.4 nM, respectively) 1 κB and GATA3, and promotes chemotherapy resistance . (A) Peripheral blood T cells from healthy donors were isolated by negative selection.
    [Show full text]
  • Press Release
    Press Release Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo’s HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201) Collaboration combines Daiichi Sankyo’s scientific and technological excellence with AstraZeneca’s global experience and resources in oncology to accelerate and expand the potential of [fam-] trastuzumab deruxtecan as monotherapy and combination therapy across a spectrum of HER2 expressing cancers AstraZeneca to pay Daiichi Sankyo up to $6.90 billion in total consideration, including $1.35 billion upfront payment and up to an additional $5.55 billion contingent upon achievement of future regulatory and sales milestones as well as other contingencies Companies to share equally development and commercialization costs as well as profits worldwide from [fam-] trastuzumab deruxtecan with Daiichi Sankyo maintaining exclusive rights in Japan Daiichi Sankyo is expected to book sales in U.S., certain countries in Europe, and certain other markets where Daiichi Sankyo has affiliates; AstraZeneca is expected to book sales in all other markets worldwide, including China, Australia, Canada and Russia Tokyo, Munich and Basking Ridge, NJ – (March 28, 2019) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it has entered into a global development and commercialization agreement with AstraZeneca for Daiichi Sankyo’s lead antibody drug conjugate (ADC), [fam-] trastuzumab deruxtecan (DS-8201), currently in pivotal development for multiple HER2 expressing cancers including breast and gastric cancer, and additional development in non-small cell lung and colorectal cancer. Daiichi Sankyo and AstraZeneca will jointly develop and commercialize [fam-] trastuzumab deruxtecan as a monotherapy or a combination therapy worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights.
    [Show full text]
  • JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
    Drugs https://doi.org/10.1007/s40265-020-01261-8 CURRENT OPINION JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors Miguel Nogueira1 · Luis Puig2 · Tiago Torres1,3 © Springer Nature Switzerland AG 2020 Abstract Despite advances in the treatment of psoriasis, there is an unmet need for efective and safe oral treatments. The Janus Kinase– Signal Transducer and Activator of Transcription (JAK–STAT) pathway plays a signifcant role in intracellular signalling of cytokines of numerous cellular processes, important in both normal and pathological states of immune-mediated infamma- tory diseases. Particularly in psoriasis, where the interleukin (IL)-23/IL-17 axis is currently considered the crucial pathogenic pathway, blocking the JAK–STAT pathway with small molecules would be expected to be clinically efective. However, relative non-specifcity and low therapeutic index of the available JAK inhibitors have delayed their integration into the therapeutic armamentarium of psoriasis. Current research appears to be focused on Tyrosine kinase 2 (TYK2), the frst described member of the JAK family. Data from the Phase II trial of BMS-986165—a selective TYK2 inhibitor—in psoriasis have been published and clinical results are encouraging, with a large Phase III programme ongoing. Further, the selective TYK2 inhibitor PF-06826647 is being tested in moderate-to-severe psoriasis in a Phase II clinical trial. Brepocitinib, a potent TYK2/JAK1 inhibitor, is also being evaluated, as both oral and topical treatment. Results of studies with TYK2 inhibitors will be important in assessing the clinical efcacy and safety of these drugs and their place in the therapeutic armamentarium of psoriasis.
    [Show full text]
  • 07052020 MR ASCO20 Curtain Raiser
    Media Release New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in cancer care First clinical data from tiragolumab, Roche’s novel anti-TIGIT cancer immunotherapy, in combination with Tecentriq® (atezolizumab) in patients with PD-L1-positive metastatic non- small cell lung cancer (NSCLC) Updated overall survival data for Alecensa® (alectinib), in people living with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC Key highlights to be shared on Roche’s ASCO virtual newsroom, 29 May 2020, 08:00 CEST Basel, 7 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 21 cancer types, will be presented at the ASCO20 Virtual Scientific Program organised by the American Society of Clinical Oncology (ASCO), which will be held 29-31 May, 2020. A total of 120 abstracts that include a Roche medicine will be presented at this year's meeting. "At ASCO, we will present new data from many investigational and approved medicines across our broad oncology portfolio," said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “These efforts exemplify our long-standing commitment to improving outcomes for people with cancer, even during these unprecedented times. By integrating our medicines and diagnostics together with advanced insights and novel platforms, Roche is uniquely positioned to deliver the healthcare solutions of the future." Together with its partners, Roche is pioneering a comprehensive approach to cancer care, combining new diagnostics and treatments with innovative, integrated data and access solutions for approved medicines that will both personalise and transform the outcomes of people affected by this deadly disease.
    [Show full text]
  • Review Tec Kinases: a Family with Multiple Roles in Immunity
    Immunity, Vol. 12, 373±382, April, 2000, Copyright 2000 by Cell Press Tec Kinases: A Family Review with Multiple Roles in Immunity Wen-Chin Yang,*³§ Yves Collette,*³ inositol phosphates, but they are thought to be relevant Jacques A. NuneÁ s,*³ and Daniel Olive*² for binding of PtdIns lipids to the same sites. In most *INSERM U119 cases, PH domains bind preferentially to PtdIns (4,5)P2 Universite de la Me diterrane e and inositol (1,4,5) P3 (Ins (1,4,5) P3). However, the Btk 13009 Marseille PH domain binds PtdIns (3,4,5)P3 and Ins (1, 3, 4, 5)P4 France the tightest. PtdIns (3, 4, 5)P3, one of the products of the action of PI3K, is thought to act as a second messen- ger to recruit regulatory proteins to the plasma mem- brane via their PH domains (see below). Many of the Antigen receptors on T, B, and mast cells are multimo- mutations in Btk that lead to XLA are point mutations lecular complexes that are activated by interactions with that cluster at one end of the PH domain and could be external signals. These signals are then transmitted to predicted to impair binding to Ins (3,4,5)P (for review regulate gene expression and posttranscriptional modi- 3 see Satterthwaite et al., 1998a) (Figure 1b). Similarly, fications. Nonreceptor tyrosine kinases (NRTK) are key CBA/N xid mice carry an R28C mutation in the Btk PH players that relay and integrate these signals. NRTK are domain. The recent structure of the PH domain from divided into distinct families defined by a prototypic Btk complexed with Ins (1,3,4,5)P4 provides an explana- member: Src, Tec, Syk, Csk, Fes, Abl, Jak, Fak, Ack, tion for several mutations associated with XLA: mis- Brk, and Srm (Bolen and Brugge, 1997).
    [Show full text]
  • Multi-Discipline Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761139Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761139} ENHERTU (fam-trastuzumab deruxtecan-nxki) NDA/BLA Multi-disciplinary Review and Evaluation Disclaimer: In this document, the sections labeled as “The Applicant’s Position” are completed by the Applicant, which do not necessarily reflect the positions of the FDA. Application Type Biologics License Application (BLA) 351(a) Application Number BLA 761139 Priority or Standard Priority Submit Date(s) August 29, 2019 Received Date(s) August 29, 2019 PDUFA Goal Date April 29, 2020 Division/Office DO1/OOD/OND/CDER Review Completion Date Electronic Stamp Date Established Name fam-trastuzumab deruxtecan-nxki (Proposed) Trade Name ENHERTU Pharmacologic Class HER2-directed antibody and topoisomerase inhibitor conjugate Code name Applicant Daiichi Sankyo, Inc Formulation(s) 100 mg lyophilized powder Dosing Regimen 5.4 mg IV every 3 weeks (b) (4) Applicant Proposed Indication(s)/Population(s) Recommendation on Accelerated Approval Regulatory Action Recommended Treatment of adult patients with unresectable or metastatic Indication(s)/Population(s) HER2-positive breast cancer who have received two or more (if applicable) prior anti-HER2-based regimens in the metastatic setting. 1 Version date: June 11, 2019 (ALL NDA/BLA reviews) Disclaimer: In this document, the sections labeled as “The Applicant’s Position” are completed by the Applicant and do not necessarily reflect the positions of the FDA. Reference ID: 4537638 NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761139} ENHERTU (fam-trastuzumab deruxtecan-nxki) Table of Contents Reviewers of Multi-Disciplinary Review and Evaluation .............................................................
    [Show full text]
  • Biomarker Testing in Non- Small Cell Lung Cancer (NSCLC)
    The biopharma business of Merck KGaA, Darmstadt, Germany operates as EMD Serono in the U.S. and Canada. Biomarker testing in non- small cell lung cancer (NSCLC) Copyright © 2020 EMD Serono, Inc. All rights reserved. US/TEP/1119/0018(1) Lung cancer in the US: Incidence, mortality, and survival Lung cancer is the second most common cancer diagnosed annually and the leading cause of mortality in the US.2 228,820 20.5% 57% Estimated newly 5-year Advanced or 1 survival rate1 metastatic at diagnosed cases in 2020 diagnosis1 5.8% 5-year relative 80-85% 2 135,720 survival with NSCLC distant disease1 Estimated deaths in 20201 2 NSCLC, non-small cell lung cancer; US, United States. 1. National Institutes of Health (NIH), National Cancer Institute. Cancer Stat Facts: Lung and Bronchus Cancer website. www.seer.cancer.gov/statfacts/html/lungb.html. Accessed May 20, 2020. 2. American Cancer Society. What is Lung Cancer? website. https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html. Accessed May 20, 2020. NSCLC is both histologically and genetically diverse 1-3 NSCLC distribution by histology Prevalence of genetic alterations in NSCLC4 PTEN 10% DDR2 3% OTHER 25% PIK3CA 12% LARGE CELL CARCINOMA 10% FGFR1 20% SQUAMOUS CELL CARCINOMA 25% Oncogenic drivers in adenocarcinoma Other or ADENOCARCINOMA HER2 1.9% 40% KRAS 25.5% wild type RET 0.7% 55% NTRK1 1.7% ROS1 1.7% Oncogenic drivers in 0% 20% 40% 60% RIT1 2.2% squamous cell carcinoma Adenocarcinoma DDR2 2.9% Squamous cell carcinoma NRG1 3.2% Large cell carcinoma
    [Show full text]
  • Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
    Published OnlineFirst October 4, 2013; DOI: 10.1158/1078-0432.CCR-13-0358 Clinical Cancer Cancer Therapy: Clinical Research See related article by Gwin and Spector, p. 278 Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy Gail D. Lewis Phillips1, Carter T. Fields1, Guangmin Li1, Donald Dowbenko1, Gabriele Schaefer1, Kathy Miller5, Fabrice Andre6, Howard A. Burris III8, Kathy S. Albain9, Nadia Harbeck10, Veronique Dieras7, Diana Crivellari11, Liang Fang2, Ellie Guardino3, Steven R. Olsen3, Lisa M. Crocker4, and Mark X. Sliwkowski1 Abstract Purpose: Targeting HER2 with multiple HER2-directed therapies represents a promising area of treatment for HER2-positive cancers. We investigated combining the HER2-directed antibody–drug con- jugate trastuzumab emtansine (T-DM1) with the HER2 dimerization inhibitor pertuzumab (Perjeta). Experimental Design: Drug combination studies with T-DM1 and pertuzumab were performed on cultured tumor cells and in mouse xenograft models of HER2-amplified cancer. In patients with HER2- positive locally advanced or metastatic breast cancer (mBC), T-DM1 was dose-escalated with a fixed standard pertuzumab dose in a 3þ3 phase Ib/II study design. Results: Treatment of HER2-overexpressing tumor cells in vitro with T-DM1 plus pertuzumab resulted in synergistic inhibition of cell proliferation and induction of apoptotic cell death. The presence of the HER3 ligand, heregulin (NRG-1b), reduced the cytotoxic activity of T-DM1 in a subset of breast cancer lines; this effect was reversed by the addition of pertuzumab. Results from mouse xenograft models showed enhanced antitumor efficacy with T-DM1 and pertuzumab resulting from the unique antitumor activities of each agent.
    [Show full text]